Literature DB >> 27206015

Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis.

Andrew R Reinink1, Terrence C Lee, Peter D R Higgins.   

Abstract

BACKGROUND: Mucosal healing (MH) in inflammatory bowel disease has been associated with improved long-term clinical outcomes. Uncertainty remains as to the magnitude of this effect and to how this association changes with time and degree of healing.
METHODS: PubMed, EMBASE, and Web of Science searches identified 1570 citations. Screening of abstracts identified 155 articles for full-text review, of which 19 met inclusion criteria. For 3 outcomes of interest (surgeries, hospitalizations, remission), weighted random-effects meta-analysis was performed.
RESULTS: In pooled analysis, MH predicted fewer major abdominal surgeries (relative risk [RR], 0.34; 95% confidence interval [CI], 0.26-0.46), increased remission (RR, 1.84; 95% CI, 1.43-2.36), and fewer hospitalizations (RR, 0.58; 95% CI, 0.42-0.78). Complete MH and partial MH both showed significantly higher rates of favorable outcomes. Separate analyses for Crohn's disease and ulcerative colitis showed identical patterns for surgeries and remission. When subjects with no healing were excluded, and complete versus partial healing was compared, rates of surgery were not significantly different (RR, 0.82; 95% CI, 0.46-1.44). However, complete healing was superior in predicting corticosteroid-free remission (RR, 1.71; 95% CI, 1.24-2.34). Meta-regression found that the predictive power of this complete versus partial healing distinction was strongly associated with the duration of follow-up after endoscopy.
CONCLUSIONS: MH is a strong predictor of fewer surgeries, long-term clinical remission, and fewer hospitalizations. Complete healing is not significantly more favorable than partial healing for predicting surgeries or hospitalizations, but it did predict higher rates of clinical remission. This benefit of complete MH over partial healing increases with follow-up time.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27206015     DOI: 10.1097/MIB.0000000000000816

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  28 in total

1.  Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.

Authors:  Abhinav Vasudevan; Ajay Raghunath; Shane Anthony; Cian Scanlon; Miles P Sparrow; Peter R Gibson; Daniel R van Langenberg
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

2.  Targeting Mucosal Healing in Crohn's Disease.

Authors:  Michael F Picco; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-10

3.  Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

Authors:  Ji Young Chang; Jae Hee Cheon; Yehyun Park; Soo Jung Park; Tae-Il Kim; Won-Ho Kim
Journal:  Dig Dis Sci       Date:  2018-07-09       Impact factor: 3.199

4.  Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial.

Authors:  Mitsuro Chiba; Kunio Nakane; Tsuyotoshi Tsuji; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Kenta Watanabe; Yu Obara; Masafumi Komatsu; Takeshi Sugawara
Journal:  Perm J       Date:  2019

Review 5.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

6.  The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine.

Authors:  Giuseppe Frieri; Brigida Galletti; Mirko Di Ruscio; Rachele Tittoni; Annalisa Capannolo; Donatella Serva; Giovanni Latella; Laura Sollima; Pietro Leocata; Stefano Necozione; Rosamarie Frieri; Angelo Viscido
Journal:  Therap Adv Gastroenterol       Date:  2017-08-25       Impact factor: 4.409

Review 7.  Eosinophilic esophagitis: What can we learn from Crohn's disease?

Authors:  Javier Molina-Infante; Alain M Schoepfer; Alfredo J Lucendo; Evan S Dellon
Journal:  United European Gastroenterol J       Date:  2016-09-29       Impact factor: 4.623

Review 8.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

9.  Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn's disease.

Authors:  Li Ma; Wenbo Li; Nan Zhuang; Hong Yang; Wei Liu; Weixun Zhou; Yuxin Jiang; Jianchu Li; Qingli Zhu; Jiaming Qian
Journal:  Therap Adv Gastroenterol       Date:  2021-06-09       Impact factor: 4.409

Review 10.  Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier.

Authors:  Cambrian Y Liu; Candace M Cham; Eugene B Chang
Journal:  Transl Res       Date:  2021-06-12       Impact factor: 10.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.